TENX logo

Tenax Therapeutics (TENX) Company Overview

Profile

Full Name:

Tenax Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

April 4, 1994

Indexes:

Not included

Description:

Tenax Therapeutics is a biopharmaceutical company focused on developing treatments for serious cardiovascular and pulmonary diseases. They work on innovative therapies to improve patient outcomes, particularly in conditions like pulmonary hypertension. Their goal is to advance healthcare through research and development of new medications.

Events Calendar

Earnings

Next earnings date:

May 14, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 31, 2021
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 3, 2024

Analyst ratings

Recent major analysts updates

Oct 24, 24 Leerink Partners
Outperform
Feb 20, 24 Roth MKM
Buy
Mar 7, 23 Roth MKM
Buy
Dec 29, 20 HC Wainwright & Co.
Buy
May 18, 17 Ladenburg Thalmann
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)
Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)
Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)
TENX
seekingalpha.comNovember 15, 2024

Tenax Therapeutics, Inc. (NASDAQ:TENX ) Guggenheim Healthcare Innovation Conference November 13, 2024 1:00 PM ET Company Participants Chris Giordano - President and CEO Stuart Rich - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Seamus Fernandez Good afternoon, everybody. And welcome again to Guggenheim Securities Inaugural Healthcare Innovation Conference.

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
TENX
globenewswire.comOctober 31, 2024

CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax's CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a session investors can attend live or via webcast.

Why Is Tenax Therapeutics (TENX) Stock Up 29% Today?
Why Is Tenax Therapeutics (TENX) Stock Up 29% Today?
Why Is Tenax Therapeutics (TENX) Stock Up 29% Today?
TENX
investorplace.comAugust 6, 2024

Tenax Therapeutics (NASDAQ: TENX ) stock is soaring higher on Tuesday after the company announced the completion of an oversubscribed private placement for its shares. This oversubscribed private placement has Tenax Therapeutics expecting $100 million in gross proceeds.

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
TENX
globenewswire.comAugust 6, 2024

CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $100 million to the Company, before deducting placement agent fees and other private placement expenses.

Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
TENX
InvestorPlaceFebruary 8, 2024

Tenax Therapeutics (NASDAQ: TENX ) stock is falling hard on Thursday after the pharmaceutical company announced details for a public offering of its shares. That public offering has Tenax Therapeutics selling 1.6 million units.

Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?
Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?
Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?
TENX
InvestorPlaceNovember 13, 2023

Shares of pharmaceutical specialist Tenax Therapeutics (NASDAD: TENX ) are skyrocketing on Monday amid encouraging regulatory news. More specifically, with a focus on addressing cardiovascular and pulmonary diseases with high unmet medical need, Tenax has received clearance for its investigational new drug (IND) application for its pulmonary hypertension therapeutic.

Tenax Therapeutics shares soar after FDA clears IND for hypertension candidate NX-103
Tenax Therapeutics shares soar after FDA clears IND for hypertension candidate NX-103
Tenax Therapeutics shares soar after FDA clears IND for hypertension candidate NX-103
TENX
Proactive InvestorsNovember 13, 2023

Shares of Tenax Therapeutics surged over 300% after it announced the US Food and Drug Administration has reviewed and cleared its Investigational New Drug (IND) application for its hypertension candidate, TNX-103. The specialty pharmaceutical company said the  FDA's enables it to proceed with the first of two Phase 3 studies for TNX-103 (oral Levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).

FAQ

  • What is the ticker symbol for Tenax Therapeutics?
  • Does Tenax Therapeutics pay dividends?
  • What sector is Tenax Therapeutics in?
  • What industry is Tenax Therapeutics in?
  • What country is Tenax Therapeutics based in?
  • When did Tenax Therapeutics go public?
  • Is Tenax Therapeutics in the S&P 500?
  • Is Tenax Therapeutics in the NASDAQ 100?
  • Is Tenax Therapeutics in the Dow Jones?
  • When was Tenax Therapeutics's last earnings report?
  • When does Tenax Therapeutics report earnings?
  • Should I buy Tenax Therapeutics stock now?

What is the ticker symbol for Tenax Therapeutics?

The ticker symbol for Tenax Therapeutics is NASDAQ:TENX

Does Tenax Therapeutics pay dividends?

No, Tenax Therapeutics does not pay dividends

What sector is Tenax Therapeutics in?

Tenax Therapeutics is in the Healthcare sector

What industry is Tenax Therapeutics in?

Tenax Therapeutics is in the Biotechnology industry

What country is Tenax Therapeutics based in?

Tenax Therapeutics is headquartered in United States

When did Tenax Therapeutics go public?

Tenax Therapeutics's initial public offering (IPO) was on April 4, 1994

Is Tenax Therapeutics in the S&P 500?

No, Tenax Therapeutics is not included in the S&P 500 index

Is Tenax Therapeutics in the NASDAQ 100?

No, Tenax Therapeutics is not included in the NASDAQ 100 index

Is Tenax Therapeutics in the Dow Jones?

No, Tenax Therapeutics is not included in the Dow Jones index

When was Tenax Therapeutics's last earnings report?

Tenax Therapeutics's most recent earnings report was on Nov 13, 2024

When does Tenax Therapeutics report earnings?

The next expected earnings date for Tenax Therapeutics is May 14, 2025

Should I buy Tenax Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions